Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 1/2 1

Status

Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 4 Prostatic Neoplasms 4 Uveal Melanoma 1 Radiation Injuries 1 Prostatic Diseases 1 Melanoma 1 Locally Advanced Cervical Carcinoma 1 Glioblastoma 1 Cervical Adenocarcinoma 1 Carcinoma, Ductal, Breast 1 Breast Neoplasms 1 Brain Neoplasms 1 Adenocarcinoma 1

Interventions

Ipilimumab 5 Nivolumab 4 pembrolizumab 3 sargramostim 2 fludarabine 2 binimetinib 2 aldesleukin 2 Interleukin-2 2 Granulocyte-Macrophage Colony-Stimulating Factor 2 Cyclophosphamide 2 trametinib 1 tebentafusp 1 sotrastaurin 1 montanide ISA 51 1 incomplete Freund's adjuvant 1 glembatumumab vedotin 1 fludarabine phosphate 1 entrectinib 1 Valproic Acid 1 Tramadol 1 Thalidomide 1 Temozolomide 1 Solutions 1 Ruthenium-106 1 Radiotherapy 1 RNA, Messenger 1 Protein Kinase C 1 Melphalan 1 Magnetic Resonance Spectroscopy 1 Ibuprofen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Uveal Melanoma × Brachytherapy × Clear all

NCT05893654 2025-09-15

MELCOM

Hospital das Clínicas de Ribeirão Preto

Phase 1/2 Enrolling by invitation

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡